Ran Fan

Ran Fan

Auto-generated profile, based on publicly available information

Ran Fan

Department of Inflammation and Immunity and

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
KAKatayoun Ayasoufi
Katayoun Ayasoufi
DZDaniel B. Zwick
Daniel B. Zwick
RFRan Fan
Ran Fan
SHSuheyla Hasgur
Suheyla Hasgur
MNMichael Nicosia
Michael Nicosia
AVAnna Valujskikh
Anna Valujskikh
Antibody-mediated lymphoablation is used in solid organ and stem cell transplantation and autoimmunity. Using murine anti-thymocyte globulin (mATG) in a mouse model of heart transplantation, we previously reported that the homeostatic recovery of CD8 + T cells requires help from depletion-resistant memory CD4 + T cells delivered through CD40-expressing B cells. This study investigated the mechanisms by which B cells mediate CD8 + T cell proliferation in lymphopenic hosts. While CD8 + T cell recovery required MHC class I expression in the host, the reconstitution occurred independently of MHC class I, MHC class II, or CD80/CD86 expression on B cells. mATG lymphoablation upregulated the B cell expression of several cytokine genes, including IL-15 and IL-27, in a CD4-dependent manner. Neither treatment with anti-CD122 mAb nor the use of IL-15Rα –/– recipients altered CD8 + T cell recovery after mATG treatment, indicating that IL-15 may be dispensable for T cell proliferation in our model. Instead, IL-27 neutralization or the use of IL-27Rα –/– CD8 + T cells inhibited CD8 + T cell proliferation and altered the phenotype and cytokine profile of reconstituted CD8 + T cells. Our findings uncover what we believe is a novel role of IL-27 in lymphopenia-induced CD8 + T cell proliferation and suggest that targeting B cell–derived cytokines may increase the efficacy of lymphoablation and improve transplant outcomes.

15 June 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
SDSreedevi Danturti
Sreedevi Danturti
KKKaren S. Keslar
Karen S. Keslar
LSLeah R. Steinhoff
Leah R. Steinhoff
RFRan Fan
Ran Fan
NDNina Dvorina
Nina Dvorina
WBWilliam Baldwin
William Baldwin
Adiponectin is a pleiotropic cytokine with diverse immunomodulatory effects on macrophages and lymphocytes. In the current paradigm, lymphocytes and macrophages respond to adiponectin that is produced by adipocytes and other parenchymal cells. Using a model of chronic arterial inflammation in cardiac transplants, we found that T cells derived from the recipient migrate to the heart and produce adiponectin locally. The evidence that T cells produce significant amounts of adiponectin is based on 3 experimental approaches. First, CD4 + T cells isolated from the blood and spleen after cardiac transplantation express mRNA for adiponectin. Second, reconstitution of T cell–deficient recipients with transgenic CD4 + T cells that express receptors for donor antigens results in arterial infiltrates containing T cells and increased mRNA expression for adiponectin in cardiac transplants. Third, CD4 + T cells isolated from the allograft secrete adiponectin in vitro. Taken together, these data indicate that adiponectin-competent cells originating in the recipient migrate into the transplant. Establishing T cells as a source of adiponectin provides a new dimension, to our knowledge, to the modulatory effects of adiponectin on immune responses.

13 May 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MNMichael Nicosia
Michael Nicosia
RFRan Fan
Ran Fan
JLJuyeun Lee
Juyeun Lee
GAGabriella L. All
Gabriella L. All
VGVictoria Gorbacheva
Victoria Gorbacheva
AVAnna Valujskikh
Anna Valujskikh
Lymphocyte activation gene 3 (LAG3) is a coinhibitory receptor expressed by various immune cells. Although the immunomodulatory potential of LAG3 is being explored in cancer and autoimmunity, there is no information on its role after organ transplantation. Our study investigated the functions of LAG3 in a mouse model of renal allograft rejection. LAG3 –/– recipients rapidly rejected MHC-mismatched renal allografts that were spontaneously accepted by WT recipients, with graft histology characteristic of antibody-mediated rejection. Depletion of recipient B cells but not CD8 + T cells significantly extended kidney allograft survival in LAG3 –/– recipients. Treatment of WT recipients with an antagonistic LAG3 antibody enhanced anti-donor immune responses and induced kidney damage associated with chronic rejection. The studies of conditional LAG3 –/– recipients and mixed bone marrow chimeras demonstrated that LAG3 expression on either T or B cells is sufficient to regulate anti-donor humoral immunity but not to induce acute allograft rejection. The numbers and proinflammatory functions of graft-infiltrating NK cells were markedly increased in LAG3 –/– recipients, suggesting that LAG3 also regulates the effector stage of antibody-mediated rejection. These findings identified LAG3 as a regulator of immune responses to kidney allografts and a potential therapeutic target for antibody-mediated rejection prevention and treatment.